This page shows the latest bosentan news and features for those working in and with pharma, biotech and healthcare.
Meanwhile, J&J claims the company's marketed products including its trio of pulmonary artery hypertension (PAH) drugs, including Tracleer (bosentan) - now facing generic competition - as well as follow-up drugs
Tracleer (bosentan) which has lost patent protection in the US and Europe. .
Actelion has been through a difficult patch after losing patent protection for pulmonary artery hypertension (PAH) blockbuster Tracleer (bosentan), but is on the up with strong growth for follow-up PAH
After a challenging couple of years following the loss of patent protection for pulmonary artery hypertension (PAH) blockbuster Tracleer (bosentan), Actelion is now riding high on the back of strong growth
Actelion's top-selling product Tracleer (bosentan) has already lost patent protection in some markets and saw sales slide 15% in the first nine months of the year to CHF 790m (
Tracleer (bosentan).
More from news
Approximately 3 fully matching, plus 20 partially matching documents found.
At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag).
Prior to this role she was a brand lead at pharma company Actelion where she spent several years on the marketing of hypertension treatment Tracleer (bosentan), during which time she worked
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...